제목2

NXC828은 Hif-1a와 VEGF를 저해하여 안구의 비정상적인 혈관 신생을 억제하는 점안 제형의
습성황반변성 치료제입니다. 안구에 레이저를 조사하여 비정상적인 신생혈관을 유발하는 CNV 모델에서
기존 주사 제형의 항체 치료제와 비교하여 안구 손상과 감염의 부작용은 없이 유효한 효과를 나타냄을 확인하였습니다.

NXC828 is a novel HIF-1α inhibitor being developed for the treatment of wet age-related macular
degeneration (wet-AMD) as an eye drop formulation. Current standard treatments for wet-AMD are
anti-VEGF intravitreal injections which entail a variety of issues such as injection-associated side effects,
fear of injection, and high medical costs. An eye drop formulation may be the solution to alleviating
these unmet medical needs by allowing patients to self-administer the medication anytime, anywhere
while avoiding injection-associated side effects.